Thomas Xavier
Service d'hématologie Clinique, Bâtiment 1G, Department of Clinical Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
Oncol Ther. 2025 Apr 18. doi: 10.1007/s40487-025-00339-1.
T cell acute lymphoblastic leukemia (T-ALL) is a class of hematological malignancies predominantly affecting children, adolescents, and young adults, marked by aggressive behavior and poor clinical response, especially in relapsing cases. Advances in molecular biology for the last decade have led to the identification of potential targetable alterations, which should lead to the development of new therapies. T oncogenesis involves not only overexpression of some oncogenes, but also deregulation of some signaling pathways, epigenetic mechanisms, and apoptosis. The present review presents the promising therapeutic agents targeting these specific alterations involved in the development of T-ALL.
T细胞急性淋巴细胞白血病（T-ALL）是一类主要影响儿童、青少年和年轻成人的血液系统恶性肿瘤，其特点是侵袭性强且临床反应不佳，尤其是在复发病例中。过去十年分子生物学的进展已导致识别出潜在的可靶向改变，这应该会带来新疗法的开发。T细胞肿瘤发生不仅涉及一些癌基因的过表达，还涉及一些信号通路、表观遗传机制和细胞凋亡的失调。本综述介绍了针对T-ALL发生过程中这些特定改变的有前景的治疗药物。
